With the newly-standalone Sandoz set to announce its first post-spinoff financial results on 24 October, analysts have been weighing the company’s prospects since its separation from former parent company Novartis earlier this month.
Analysts Weigh Sandoz Prospects Ahead Of First Standalone Results
Jefferies Says Market Sees Post-Spinoff Sandoz As ‘A Show Me Money Story’
As industry onlookers await Sandoz’s first financial results as a standalone company, analysts have offered their initial impressions following the firm’s separation from former parent Novartis.
More from Earnings
More from Business
• By
Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.
• By
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
• By
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.